HOXB2, FRZB, and KRT13 methylation status may be potential prognostic biomarkers to predict the likelihood of getting high grade non-invasive bladder cancer, that can subsequently be used to predict tumor recurrence or progression to muscle-invasion [46]. This evidence concerns the gene FRZB and urinary bladder cancer.